In 2023, the total expenditure on health care in China reached over ************* yuan. That figure included government spending, collective spending, and private out-of-pocket spending on health care. Health expenditures worldwide The health expenditure in China has soared from under *********** yuan in 2000 to more than ************* in 2023. The reasons behind this growth are multifold. Most important factors are the increasing living standards and the aging of the population. In terms of relative numbers, health expenditure as a proportion of Gross Domestic Product (GDP) has also been increasing in general in the last two decades and reached over *** percent in recent years. This indicates the growing importance the government attributed to the health care in the country. However, this is still a relatively low share of GDP when compared to other more developed countries, for example Australia or South Korea. Health care in China The same phenomenon is reflected in the increase in private per capita health expenditure of Chinese households as well, which has nearly tripled in the last decade for Beijing, as the region with the highest private health expenditure in China. Health insurance is voluntary in China, but the share of the population being covered by a basic health insurance has grown quickly in the last ten years. In 2017, the number of people covered by basic health insurance surpassed *********** for the first time. In 2019, more than ** percent of the population enjoyed at least a basic health insurance. Additional commercial health insurances were especially purchased by people working as executives or professionals.

The China digital health market size reached USD 81.3 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 328.8 Billion by 2033, exhibiting a growth rate (CAGR) of 16.8% during 2025-2033. The market is thriving, driven by technological advancements, government support, and a growing demand for telemedicine, AI diagnostics, and health apps. It is further witnessing rapid growth with increased investment in digital healthcare infrastructure and innovative health tech solutions, enhancing accessibility and quality of care across the country.

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level for 2025-2033. Our report has categorized the market based on type and component.

In 2023, health expenditure in China amounted to about **** percent of the GDP, up from **** percent in the previous year. Rising healthcare expenditure In the past four decades, China's overall healthcare spending has increased consistently. Growing government funding and private investments have led to an expansion of the health system, resulting in more healthcare facilities, more beds, and improved medical technologies. At present, more than ********* of the nation's healthcare expenditures are out-of-pocket costs borne by patients, with the rest covered by government subsidies and medical insurance. The improved medical insurance system At the turn of this century, China introduced a range of statutory medical insurance programs, including the Urban Employee Basic Medical Insurance, the New Rural Cooperative Medical Scheme, and the Urban Resident Basic Medical Insurance. The programs gradually reduced the high out-of-pocket medical bills borne by Chinese patients, while providing a more stable source of income for the healthcare providers. Since around 2017, the basic medical insurance system was simplified, resulting in two insurance schemes covering ** percent of the population.

China Consumption Expenditure per Capita: Health Care and Medical Services data was reported at 2,547.000 RMB in 2024. This records an increase from the previous number of 2,460.000 RMB for 2023. China Consumption Expenditure per Capita: Health Care and Medical Services data is updated yearly, averaging 743.700 RMB from Dec 1998 (Median) to 2024, with 27 observations. The data reached an all-time high of 2,547.000 RMB in 2024 and a record low of 173.200 RMB in 2000. China Consumption Expenditure per Capita: Health Care and Medical Services data remains active status in CEIC and is reported by National Bureau of Statistics. The data is categorized under China Premium Database’s Household Survey – Table CN.HD: Expenditure per Capita.

In 2023, social health expenditure, which includes mainly inputs from social medical security contributions and commercial medical insurance, accounted for nearly 42 percent of the total health spending in China. The other 58 percent is almost equally divided by government expenditure and cash payments of residents when receiving medical and health services.

China Government Expenditure: Health and Family Planning data was reported at 233.600 RMB bn in Mar 2025. This records a decrease from the previous number of 246.100 RMB bn for Dec 2024. China Government Expenditure: Health and Family Planning data is updated monthly, averaging 84.877 RMB bn from Jan 2007 (Median) to Mar 2025, with 203 observations. The data reached an all-time high of 311.100 RMB bn in Dec 2022 and a record low of 5.840 RMB bn in Jan 2007. China Government Expenditure: Health and Family Planning data remains active status in CEIC and is reported by Ministry of Finance. The data is categorized under China Premium Database’s Government and Public Finance – Table CN.FA: Government Revenue and Expenditure: Monthly.

China Total Expenditure on Public Health data was reported at 9,057,581.000 RMB mn in 2023. This records an increase from the previous number of 8,532,749.000 RMB mn for 2022. China Total Expenditure on Public Health data is updated yearly, averaging 480,627.691 RMB mn from Dec 1978 (Median) to 2023, with 46 observations. The data reached an all-time high of 9,057,581.000 RMB mn in 2023 and a record low of 11,021.000 RMB mn in 1978. China Total Expenditure on Public Health data remains active status in CEIC and is reported by National Health Commission. The data is categorized under China Premium Database’s Socio-Demographic – Table CN.GN: Expenditure on Public Health.

China: Healthcare price index, world average = 100: The latest value from 2021 is 63.77 index points, an increase from 61.64 index points in 2017. In comparison, the world average is 67.78 index points, based on data from 165 countries. Historically, the average for China from 2017 to 2021 is 62.71 index points. The minimum value, 61.64 index points, was reached in 2017 while the maximum of 63.77 index points was recorded in 2021.

BackgroundHealthcare workers' relationship with industry is not merely an agent mediating between consumer and vendor, but they are also inventors of the interventions they exist to deliver. Driven by the background of the digital health era, scientific research and technological (Sci-tech) innovation in the medical field are becoming more and more closely integrated. However, scholars shed little light on Sci-tech relevance to evaluate the innovation performance of healthcare organizations, a distinctive feature of healthcare organizations' innovation in the digital health era.MethodsAcademic publications and patents are the manifestations of scientific research outputs and technological innovation outcomes, respectively. The study extracted data from publications and patents of 159 hospitals in China to evaluate their innovation performance. A total of 18 indicators were constructed, four of which were based on text similarity match and represented the Sci-tech relevance. We then applied factor analyses, analytical hierarchy process, and logistic regression to construct an evaluation model. We also examined the relationship between hospitals' innovation performance and their geographical locations. Finally, we implemented a mediation analysis to show the influence of digital health on hospital innovation performance.ResultsA total of 16 indicators were involved, four of which represented the Sci-tech including the number of articles matched per patent (NAMP), the number of patents matched per article (NPMA), the proportion of highly matched patents (HMP), and the proportion of highly matched articles (HMA). Indicators of HMP (r = 0.52, P = 2.40 × 10−12), NAMP (r = 0.52, P = 2.54 × 10−12), and NPMA (r = 0.51, P = 5.53 × 10−12) showed a strong positive correlation with hospital innovation performance score. The evaluation model in this study was different from other Chinese existing hospital ranking systems. The regional innovation performance index (RIP) of healthcare organizations is highly correlated with per capita disposable income (r = 0.58) and regional GDP (r = 0.60). There was a positive correlation between digital health innovation performance scores and overall hospital innovation performance scores (r = 0.20). In addition, the hospitals' digital health innovation performance affected the hospital's overall innovation score with the mediation of Sci-tech relevance indicators (NPMA and HMA). The hospitals' digital health innovation performance score showed a significant correlation with the number of healthcare workers (r = 0.44).ConclusionThis study constructed an assessment model with four invented indicators focusing on Sci-tech relevance to provide a novel tool for researchers to evaluate the innovation performance of healthcare organizations in the digital health era. The regions with high RIP were concentrated on the eastern coastal areas with a higher level of economic development. Therefore, the promotion of scientific and technological innovation policies could be carried out in advance in areas with better economic development. The innovations in the digital health field by healthcare workers enhance the Sci-tech relevance in hospitals and boost their innovation performance. The development of digital health in hospitals depends on the input of medical personnel.

China Internet Medical, Health Care Article: Taobao Online Sales: YoY: Product Average Price data was reported at -45.790 % in Aug 2020. This records an increase from the previous number of -69.870 % for Jul 2020. China Internet Medical, Health Care Article: Taobao Online Sales: YoY: Product Average Price data is updated monthly, averaging -7.950 % from Jun 2019 (Median) to Aug 2020, with 15 observations. The data reached an all-time high of 73.400 % in Dec 2019 and a record low of -78.330 % in Jun 2020. China Internet Medical, Health Care Article: Taobao Online Sales: YoY: Product Average Price data remains active status in CEIC and is reported by Moojing Market Intelligence. The data is categorized under China Premium Database’s Consumer Goods and Services – Table CN.HTB: Taobao and Tmall Online Sales: YoY: Food, Beverage and Medicine.

A survey conducted in 2023 showed that almost **** of the predominantly young respondents experienced emotional issues such as anxiety and depression in the past year. Unsatisfactory skin conditions, undesirable body shapes, and poor sleep quality were also prominent health issues. ************ respondents also reported fears of cancer, while heart problems or gout were less common.

China Number of Hospital: Traditional Chinese Medicine data was reported at 5,053.000 Unit in 2023. This records an increase from the previous number of 4,779.000 Unit for 2022. China Number of Hospital: Traditional Chinese Medicine data is updated yearly, averaging 2,441.000 Unit from Dec 1950 (Median) to 2023, with 51 observations. The data reached an all-time high of 5,053.000 Unit in 2023 and a record low of 4.000 Unit in 1950. China Number of Hospital: Traditional Chinese Medicine data remains active status in CEIC and is reported by National Health Commission. The data is categorized under China Premium Database’s Socio-Demographic – Table CN.GN: Number of Hospital & Health Center.

China Health Insurance Market By Size, Share, Trends, Growth, Forecast 2018-2028, Segmented By Type of Insurance Provider, By Type of Coverage, By Mode of Purchase, By Premium Type, By Region, By Company Forecast and Opportunities

Total Expenditure on Public Health: Shanghai data was reported at 263,422.000 RMB mn in 2020. This records an increase from the previous number of 253,268.000 RMB mn for 2019. Total Expenditure on Public Health: Shanghai data is updated yearly, averaging 153,660.000 RMB mn from Dec 2009 (Median) to 2020, with 11 observations. The data reached an all-time high of 263,422.000 RMB mn in 2020 and a record low of 65,666.000 RMB mn in 2009. Total Expenditure on Public Health: Shanghai data remains active status in CEIC and is reported by National Health Commission. The data is categorized under China Premium Database’s Socio-Demographic – Table CN.GN: Expenditure on Public Health.

Abstract

Different countries have different health outcomes that are in part due to the way respective health systems perform. Regardless of the type of health system, individuals will have health and non-health expectations in terms of how the institution responds to their needs. In many countries, however, health systems do not perform effectively and this is in part due to lack of information on health system performance, and on the different service providers.

The aim of the WHO World Health Survey is to provide empirical data to the national health information systems so that there is a better monitoring of health of the people, responsiveness of health systems and measurement of health-related parameters.

The overall aims of the survey is to examine the way populations report their health, understand how people value health states, measure the performance of health systems in relation to responsiveness and gather information on modes and extents of payment for health encounters through a nationally representative population based community survey. In addition, it addresses various areas such as health care expenditures, adult mortality, birth history, various risk factors, assessment of main chronic health conditions and the coverage of health interventions, in specific additional modules.

The objectives of the survey programme are to: 1. develop a means of providing valid, reliable and comparable information, at low cost, to supplement the information provided by routine health information systems. 2. build the evidence base necessary for policy-makers to monitor if health systems are achieving the desired goals, and to assess if additional investment in health is achieving the desired outcomes. 3. provide policy-makers with the evidence they need to adjust their policies, strategies and programmes as necessary.

Geographic coverage

The survey sampling frame must cover 100% of the country's eligible population, meaning that the entire national territory must be included. This does not mean that every province or territory need be represented in the survey sample but, rather, that all must have a chance (known probability) of being included in the survey sample.

There may be exceptional circumstances that preclude 100% national coverage. Certain areas in certain countries may be impossible to include due to reasons such as accessibility or conflict. All such exceptions must be discussed with WHO sampling experts. If any region must be excluded, it must constitute a coherent area, such as a particular province or region. For example if ¾ of region D in country X is not accessible due to war, the entire region D will be excluded from analysis.

Analysis unit

Households and individuals

Universe

The WHS will include all male and female adults (18 years of age and older) who are not out of the country during the survey period. It should be noted that this includes the population who may be institutionalized for health reasons at the time of the survey: all persons who would have fit the definition of household member at the time of their institutionalisation are included in the eligible population.

If the randomly selected individual is institutionalized short-term (e.g. a 3-day stay at a hospital) the interviewer must return to the household when the individual will have come back to interview him/her. If the randomly selected individual is institutionalized long term (e.g. has been in a nursing home the last 8 years), the interviewer must travel to that institution to interview him/her.

The target population includes any adult, male or female age 18 or over living in private households. Populations in group quarters, on military reservations, or in other non-household living arrangements will not be eligible for the study. People who are in an institution due to a health condition (such as a hospital, hospice, nursing home, home for the aged, etc.) at the time of the visit to the household are interviewed either in the institution or upon their return to their household if this is within a period of two weeks from the first visit to the household.

Kind of data

Sample survey data [ssd]

Sampling procedure

SAMPLING GUIDELINES FOR WHS

Surveys in the WHS program must employ a probability sampling design. This means that every single individual in the sampling frame has a known and non-zero chance of being selected into the survey sample. While a Single Stage Random Sample is ideal if feasible, it is recognized that most sites will carry out Multi-stage Cluster Sampling.

The WHS sampling frame should cover 100% of the eligible population in the surveyed country. This means that every eligible person in the country has a chance of being included in the survey sample. It also means that particular ethnic groups or geographical areas may not be excluded from the sampling frame.

The sample size of the WHS in each country is 5000 persons (exceptions considered on a by-country basis). An adequate number of persons must be drawn from the sampling frame to account for an estimated amount of non-response (refusal to participate, empty houses etc.). The highest estimate of potential non-response and empty households should be used to ensure that the desired sample size is reached at the end of the survey period. This is very important because if, at the end of data collection, the required sample size of 5000 has not been reached additional persons must be selected randomly into the survey sample from the sampling frame. This is both costly and technically complicated (if this situation is to occur, consult WHO sampling experts for assistance), and best avoided by proper planning before data collection begins.

All steps of sampling, including justification for stratification, cluster sizes, probabilities of selection, weights at each stage of selection, and the computer program used for randomization must be communicated to WHO

STRATIFICATION

Stratification is the process by which the population is divided into subgroups. Sampling will then be conducted separately in each subgroup. Strata or subgroups are chosen because evidence is available that they are related to the outcome (e.g. health, responsiveness, mortality, coverage etc.). The strata chosen will vary by country and reflect local conditions. Some examples of factors that can be stratified on are geography (e.g. North, Central, South), level of urbanization (e.g. urban, rural), socio-economic zones, provinces (especially if health administration is primarily under the jurisdiction of provincial authorities), or presence of health facility in area. Strata to be used must be identified by each country and the reasons for selection explicitly justified.

Stratification is strongly recommended at the first stage of sampling. Once the strata have been chosen and justified, all stages of selection will be conducted separately in each stratum. We recommend stratifying on 3-5 factors. It is optimum to have half as many strata (note the difference between stratifying variables, which may be such variables as gender, socio-economic status, province/region etc. and strata, which are the combination of variable categories, for example Male, High socio-economic status, Xingtao Province would be a stratum).

Strata should be as homogenous as possible within and as heterogeneous as possible between. This means that strata should be formulated in such a way that individuals belonging to a stratum should be as similar to each other with respect to key variables as possible and as different as possible from individuals belonging to a different stratum. This maximises the efficiency of stratification in reducing sampling variance.

MULTI-STAGE CLUSTER SELECTION

A cluster is a naturally occurring unit or grouping within the population (e.g. enumeration areas, cities, universities, provinces, hospitals etc.); it is a unit for which the administrative level has clear, nonoverlapping boundaries. Cluster sampling is useful because it avoids having to compile exhaustive lists of every single person in the population. Clusters should be as heterogeneous as possible within and as homogenous as possible between (note that this is the opposite criterion as that for strata). Clusters should be as small as possible (i.e. large administrative units such as Provinces or States are not good clusters) but not so small as to be homogenous.

In cluster sampling, a number of clusters are randomly selected from a list of clusters. Then, either all members of the chosen cluster or a random selection from among them are included in the sample. Multistage sampling is an extension of cluster sampling where a hierarchy of clusters are chosen going from larger to smaller.

In order to carry out multi-stage sampling, one needs to know only the population sizes of the sampling units. For the smallest sampling unit above the elementary unit however, a complete list of all elementary units (households) is needed; in order to be able to randomly select among all households in the TSU, a list of all those households is required. This information may be available from the most recent population census. If the last census was >3 years ago or the information furnished by it was of poor quality or unreliable, the survey staff will have the task of enumerating all households in the smallest randomly selected sampling unit. It is very important to budget for this step if it is necessary and ensure that all households are properly enumerated in order that a representative sample is obtained.

It is always best to have as many clusters in the PSU as possible. The reason for this is that the fewer the number of respondents in each PSU, the lower will be the clustering effect which

The size of the China Animal Health Industry market was valued at USD 1.04 Million in 2023 and is projected to reach USD 1.43 Million by 2032, with an expected CAGR of 4.69% during the forecast period. An expanding Chinese animal health industry is growing on the back of increasing demand for animal protein, awareness of animal health, and food safety as well as quality. These are matched by an increase in veterinary product consumption and services-vaccines, pharmaceuticals, and diagnostics-growth in the country's expansion of livestock and aquaculture. Major growth drivers in the market include increased cases of animal diseases, as well as growing policies in animal health and welfare. The Chinese government is heavily investing in animal health infrastructure that encourages the application of modern veterinary practices and technology to improve the prevention and control of diseases, including strengthening biosecurity measures in livestock and aquaculture production. In recent years, the pet population has increased in cities around the world. The more the number of pets, the higher the demand for companion animal health products, this includes preventive care, diagnostics, and nutritional supplements. Again, premium animal health products will be a result of richer disposable incomes for Chinese consumers, as they become perceived as better. Geographically, major cities such as Beijing and Shanghai happen to be the main markets because of high population densities and relatively good veterinary care infrastructure. But regional geographies are gaining importance in recent times since there is growing awareness of animal health in the regions. The China animal health industry is poised to continue its expansion pattern since it was crucial for the country in securing food supplies and further improving the health and welfare of the animals. Recent developments include: March 2023: i-Tail Corporation PCL reported an exclusivity contract with Nanjing Jiabei PetCare Products Co., Ltd, an importer and distributor of pet care products. The partnership is key in supporting the growth of ITC's business in China., July 2022: JD Health acquired a pet care business pertaining to the purchase of pet health product categories, including prescription drugs/ prescription diet, pet nutrition, pet deworming, pet milk powder, pet mouth, ear and eye cleaning, and more.. Key drivers for this market are: Increase in Pet Adoption in China, Increasing Initiatives by the Governments and Animal Welfare Associations; Advanced Technology in Animal Healthcare. Potential restraints include: Use of Counterfeit Medicines, Increasing Costs of Animal Testing and Veterinary Care. Notable trends are: Vaccines Contributed the significant Market Share Share in Terms of Revenues in the Therapeutics Segment.

Market Size statistics on the Health Clinics industry in China

ObjectiveThis paper examines the impact of healthcare industry convergence on the performance of the public health system in the eastern, central, and western regions of China.MethodsPublic health performance was measured by a composite index of three standards: average life expectancy at birth, perinatal mortality, and maternal mortality. The healthcare industry convergence was measured using a coupling coordination degree method. The spatial lag, spatial error, and spatial Durbin models were used to estimate the effect of healthcare industry convergence on public health system performance and this effect’s spatial dependence and heterogeneity across eastern, central, and western China using panel data from 30 Chinese provinces from 2002 to 2019.ResultsThe convergence of the healthcare industry significantly promotes regional public health [β =0.576, 95% CI: (0.331,0.821)]. However, the convergence does not have a spatial spillover effect on the public health system at the national level. Additionally, analysis of regional heterogeneity shows that the direct effects of healthcare industry convergence on public health are positive and statistically significant for Eastern China, statistically insignificant for Central China, and positive and statistically significant for Western China. The indirect effects are negative, statistically significant, positive, statistically significant, and statistically insignificant for these three regions, respectively.ConclusionPolicy efforts should strengthen the convergence between the healthcare industry and relevant industries. It can produce more current healthcare services to improve public health and reduce regional health inequality.

The China health insurance market size reached USD 321.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 596.1 Billion by 2033, exhibiting a growth rate (CAGR) of 7.10% during 2025-2033. The market is primarily driven by the increasing number of chronic ailments, the widespread adoption of supportive government policies, the growing geriatric population, and the rising demand for higher-quality medical services in China.

Forecast: Government Expenditure on Health in China 2024 - 2028 Discover more data with ReportLinker!